Panel: SPC Case Law Review – Determine Your Strategic Considerations for 2026
Michael Pears will join a panel of leading IP professionals at the Life Science Strategy Summit on IP & Exclusivity 2025. Together, they’ll explore recent SPC rulings and discuss how these decisions are shaping exclusivity strategies across Europe. The session will offer practical takeaways to help companies plan ahead for 2026.
Topics include:
- A closer look at Article 3a and 3c referrals and their impact on combination SPCs
- Insights into the Article 1b Halozyme case and its broader implications
- Discussion on how recent rulings are influencing SPC practices across European jurisdictions
Panelists:
- Roberto Romandini, Legal Member, Boards of Appeal, EPO
- James Horgan, Chief IP Counsel – Policy & Litigation, MSD
- Michal Porubsky, Associate General Counsel, Novo Nordisk
- Michael Pears, Partner, Potter Clarkson
- Bianca Vos, Partner, Hoffmann Eitle
.jpg)
%203.jpg)
.jpg)
%20(1).jpg)
